Investor Alert

Dec. 22, 2006, 11:00 a.m. EST

Oncolytics starts patient enrollment in Reolysin trial

SAN FRANCISCO (MarketWatch) -- Oncolytics Biotech Inc. (NAS:ONCY) (TSE:CA:ONC) said Friday it has begun patient enrolment in its U.K. Phase II clinical trial to evaluate the anti-tumor effects of Reolysin in combination with low-dose radiation in patients with advanced cancers. Shares of Calgary, Alberta-based Oncolytics rose 12% to $2.02 in Friday morning trade.

Link to MarketWatch's Slice.